<!--
Filename: 	Treatment.md
Project: 	/Users/shume/Developer/mnemosyne/docs/MMB/docs/b_Hepa
Author: 	shumez <https://github.com/shumez>
Created: 	2019-09-04 15:07:6
Modified: 	2019-09-04 16:18:55
-----
Copyright (c) 2019 shumez
-->

# Treatment

## Hepatitis Drug

HB 

![](https://raw.githubusercontent.com/shumez/mnemosyne/master/docs/MMB/docs/img/b_Hepa/hb_drug.jpg)

HC

![](https://raw.githubusercontent.com/shumez/mnemosyne/master/docs/MMB/docs/img/b_Hepa/hc_drug.jpg)

**SVR** Sustained virological response 持続性ウイルス学的著効  
e.g., 

- HC
    - 治療終了から6mo
    - 血液検査, HCV-RNA(–) が維持される



<!-- <h6 id='hepatitis_drug-def'>Definition</h6> -->
<!-- <h6 id='hepatitis_drug-eti'>Etiology</h6> -->
<!-- <h6 id='hepatitis_drug-epi'>Epidemiology</h6> -->
<!-- <h6 id='hepatitis_drug-cls'>Classification</h6> -->
<!-- <h6 id='hepatitis_drug-sx'>Sign and Symptom</h6> -->
<!-- <h6 id='hepatitis_drug-cmp'>Complication</h6> -->
<!-- <h6 id='hepatitis_drug-ex'>Examination</h6> -->
<!-- <h6 id='hepatitis_drug-dx'>Diagnosis</h6> -->
<!-- <h6 id='hepatitis_drug-tx'>Treatment</h6> -->
<!-- <h6 id='hepatitis_drug-prg'>Prognosis</h6> -->
<!-- <h6 id='hepatitis_drug-app'>Appendix</h6> -->


### IFN

Interferon

<h6 id='ifn-cls'>Classification</h6>

<table>
    <thead>
        <tr>
            <th width=25%></th>
            <th width=50% colspan=2>IFN-&alpha;</th>
            <th width=25%>IFN-&beta;</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <th></th>
            <td width=25%>&alpha;</td>
            <td width=25%>&alpha; 2a, &alpha; 2b</td>
            <td>&beta;</td>
        </tr>
        <tr>
            <th>産生細胞</th>
            <td colspan=2>WBC</td>
            <td>Fibroblast</td>
        </tr>
        <tr>
            <th>投与</th>
            <td colspan=2>筋注, 皮下注</td>
            <td>IV</td>
        </tr>
        <tr>
            <th>製剤</th>
            <td>天然型</td>
            <td>遺伝子組み換え</td>
            <td>天然型</td>
        </tr>
    </tbody>
</table>

<h6 id='inf-ph'>Pharmacology</h6>

![](https://ars.els-cdn.com/content/image/1-s2.0-S2211383514000628-gr1.jpg)

[Menghao Huang, 2014](https://www.sciencedirect.com/science/article/pii/S2211383514000628)

<h6 id='inf-ind'>Indication</h6>

- HB 慢性肝炎
    - HBeAg の陰性化
    - HBV-DNAの低下
    - ALT 持続的正常化
- HC 慢性肝炎
    - HCV 陰性化
    - AST/ALT 正常化
    - 発がんの予防

<h6 id='inf-ae'>Adverse Effect</h6>

- 発熱
- 間質性肺炎
- 抑うつ
- &darr;WBC, &darr;Plt

<h6 id='inf-ci'>Contraindication</h6>

- 自己免疫性肝炎
- 小柴胡湯 投与中
- IFN 過敏症

<!-- <h6 id='-sx'>Sign and Symptom</h6> -->
<!-- <h6 id='-cmp'>Complication</h6> -->
<!-- <h6 id='-ex'>Examination</h6> -->
<!-- <h6 id='-dx'>Diagnosis</h6> -->
<!-- <h6 id='-tx'>Treatment</h6> -->
<!-- <h6 id='-prg'>Prognosis</h6> -->
<!-- <h6 id='-app'>Appendix</h6> -->


### Nucleotide Analog

核酸アナログ

- Entecavir ETV (エンテカビル&reg; バラクルード&reg;)
- **Lamivudine LMV** (ゼフィックス&reg;)
- Adefovir ADV (ヘプセラ&reg;)
- Tenofovir TDF (テノゼット&reg; ベムリディ&reg;)

<h6 id='neocleotide_analog-ph'>Pharmacology</h6>

逆転写酵素阻害 &rArr; ウイルス複製の抑制

<h6 id='neocleotide_analog-ind'>Indication</h6>

- HBV-DNA(+) HB慢性肝炎

<!-- <h6 id='neocleotide_analog-def'>Definition</h6> -->

<!-- <h6 id='neocleotide_analog-eti'>Etiology</h6> -->
<!-- <h6 id='neocleotide_analog-epi'>Epidemiology</h6> -->
<!-- <h6 id='neocleotide_analog-cls'>Classification</h6> -->
<!-- <h6 id='neocleotide_analog-sx'>Sign and Symptom</h6> -->
<!-- <h6 id='neocleotide_analog-cmp'>Complication</h6> -->
<!-- <h6 id='neocleotide_analog-ex'>Examination</h6> -->
<!-- <h6 id='neocleotide_analog-dx'>Diagnosis</h6> -->
<!-- <h6 id='neocleotide_analog-tx'>Treatment</h6> -->
<!-- <h6 id='neocleotide_analog-prg'>Prognosis</h6> -->
<!-- <h6 id='neocleotide_analog-app'>Appendix</h6> -->


### Ribavirin

レベトール&reg;, マイラン&reg;

<!-- <h6 id='ribavirin-def'>Definition</h6> -->
<h6 id='ribavirin-ind'>Indication</h6>

- 高ウイルス量のHC

<!-- <h6 id='ribavirin-def'>Definition</h6> -->
<!-- <h6 id='ribavirin-eti'>Etiology</h6> -->
<!-- <h6 id='ribavirin-epi'>Epidemiology</h6> -->
<!-- <h6 id='ribavirin-cls'>Classification</h6> -->
<!-- <h6 id='ribavirin-sx'>Sign and Symptom</h6> -->
<!-- <h6 id='ribavirin-cmp'>Complication</h6> -->
<!-- <h6 id='ribavirin-ex'>Examination</h6> -->
<!-- <h6 id='ribavirin-dx'>Diagnosis</h6> -->
<!-- <h6 id='ribavirin-tx'>Treatment</h6> -->
<!-- <h6 id='ribavirin-prg'>Prognosis</h6> -->
<!-- <h6 id='ribavirin-app'>Appendix</h6> -->


### DAAs

Direct Acting Antivirals 直接作用型抗ウイルス薬

<h6 id='daas-ph'>Pharmacology</h6>



<!-- <h6 id='daas-def'>Definition</h6> -->
<!-- <h6 id='daas-def'>Definition</h6> -->
<!-- <h6 id='daas-def'>Definition</h6> -->
<!-- <h6 id='daas-eti'>Etiology</h6> -->
<!-- <h6 id='daas-epi'>Epidemiology</h6> -->
<h6 id='daas-cls'>Classification</h6>

![](https://www.pharmaceutical-journal.com/Pictures/580xAny/6/0/1/1073601_therapeutic-targets-in-hcv-replication-cycle-17V2.png)


- NS3/4A protease inhibitors
- NS5A inhibitors
- NS5B polymerase inhibitors

[Dost Sarpel, 2017](https://www.pharmaceutical-journal.com/research/an-update-on-the-management-of-chronic-hepatitis-b-and-c-infection/20203306.article?firstPass=false)

<!-- <h6 id='daas-sx'>Sign and Symptom</h6> -->
<!-- <h6 id='daas-cmp'>Complication</h6> -->
<!-- <h6 id='daas-ex'>Examination</h6> -->
<!-- <h6 id='daas-dx'>Diagnosis</h6> -->
<!-- <h6 id='daas-tx'>Treatment</h6> -->
<!-- <h6 id='daas-prg'>Prognosis</h6> -->
<!-- <h6 id='daas-app'>Appendix</h6> -->


### Glycyrrhizin 

グリチルリチン (強力ネオミノファーゲンシー&reg;)

<h6 id='glycyrrhizin-ph'>Pharmacology</h6>

甘草

<h6 id='glycyrrhizin-ae'>Adverse Effect</h6>

- **偽性アルドステロン症**
    - &darr;K
    - HTN

<!-- <h6 id='glycyrrhizin-def'>Definition</h6> -->
<!-- <h6 id='glycyrrhizin-def'>Definition</h6> -->
<!-- <h6 id='glycyrrhizin-eti'>Etiology</h6> -->
<!-- <h6 id='glycyrrhizin-epi'>Epidemiology</h6> -->
<!-- <h6 id='glycyrrhizin-cls'>Classification</h6> -->
<!-- <h6 id='glycyrrhizin-sx'>Sign and Symptom</h6> -->
<!-- <h6 id='glycyrrhizin-cmp'>Complication</h6> -->
<!-- <h6 id='glycyrrhizin-ex'>Examination</h6> -->
<!-- <h6 id='glycyrrhizin-dx'>Diagnosis</h6> -->
<!-- <h6 id='glycyrrhizin-tx'>Treatment</h6> -->
<!-- <h6 id='glycyrrhizin-prg'>Prognosis</h6> -->
<!-- <h6 id='glycyrrhizin-app'>Appendix</h6> -->


## Lactulose 

(モニラック&reg;)

<h6 id='lactulose-ph'>Pharmacology</h6>


<h6 id='lactulose-ind'>Indication</h6>

- **肝性脳症**
- 便秘



<!-- <h6 id='lactulose-def'>Definition</h6> -->
<!-- <h6 id='lactulose-def'>Definition</h6> -->
<!-- <h6 id='lactulose-def'>Definition</h6> -->
<!-- <h6 id='lactulose-def'>Definition</h6> -->
<!-- <h6 id='lactulose-eti'>Etiology</h6> -->
<!-- <h6 id='lactulose-epi'>Epidemiology</h6> -->
<!-- <h6 id='lactulose-cls'>Classification</h6> -->
<!-- <h6 id='lactulose-sx'>Sign and Symptom</h6> -->
<!-- <h6 id='lactulose-cmp'>Complication</h6> -->
<!-- <h6 id='lactulose-ex'>Examination</h6> -->
<!-- <h6 id='lactulose-dx'>Diagnosis</h6> -->
<!-- <h6 id='lactulose-tx'>Treatment</h6> -->
<!-- <h6 id='lactulose-prg'>Prognosis</h6> -->
<!-- <h6 id='lactulose-app'>Appendix</h6> -->


## UDCA

Ursodeoxycholic Acid (ウルソ&reg;)

<!-- <h6 id='-def'>Definition</h6> -->
<!-- <h6 id='-eti'>Etiology</h6> -->
<!-- <h6 id='-epi'>Epidemiology</h6> -->
<!-- <h6 id='-cls'>Classification</h6> -->
<!-- <h6 id='-sx'>Sign and Symptom</h6> -->
<!-- <h6 id='-cmp'>Complication</h6> -->
<!-- <h6 id='-ex'>Examination</h6> -->
<!-- <h6 id='-dx'>Diagnosis</h6> -->
<!-- <h6 id='-tx'>Treatment</h6> -->
<!-- <h6 id='-prg'>Prognosis</h6> -->
<!-- <h6 id='-app'>Appendix</h6> -->

##
<!-- ## -->
<!-- <h6 id='-def'>Definition</h6> -->
<!-- <h6 id='-eti'>Etiology</h6> -->
<!-- <h6 id='-epi'>Epidemiology</h6> -->
<!-- <h6 id='-cls'>Classification</h6> -->
<!-- <h6 id='-sx'>Sign and Symptom</h6> -->
<!-- <h6 id='-cmp'>Complication</h6> -->
<!-- <h6 id='-ex'>Examination</h6> -->
<!-- <h6 id='-dx'>Diagnosis</h6> -->
<!-- <h6 id='-tx'>Treatment</h6> -->
<!-- <h6 id='-prg'>Prognosis</h6> -->
<!-- <h6 id='-app'>Appendix</h6> -->

<!-- toc -->
[01]: #
[0101]: #

<!-- ref -->

<!-- fig -->

<!-- term -->

<!--
<style type="text/css">
	img{width: 51%; float: right;}
</style>
-->